For most of the last twenty years, perimenopause has been talked about as a hormone problem. Hot flushes, irregular periods, mood changes — symptoms to be tolerated, perhaps softened by lifestyle, eventually resolved when the menstrual cycle stopped altogether. Hormone replacement therapy (HRT) was discussed nervously, in the long shadow of the 2002 Women's Health Initiative scare, and prescribed cautiously when at all.

That conversation has been turned almost entirely upside down. Three things have changed.

First, the WHI re-analyses and subsequent trials have shown that the original conclusions were drawn from women on average more than a decade past menopause — a population for whom HRT was being offered too late and in the wrong form. For women within ten years of their final period and under sixty, the risk-benefit picture for modern, body-identical HRT is dramatically more favourable than the public health messaging of the 2000s suggested.

Second — and this is the part that has shifted my own clinical thinking the most — perimenopause has been reframed as a neurological event, not just an ovarian one. The brain has more estrogen receptors than almost any other organ. When ovarian estrogen production becomes erratic and then declines, the brain is not a passive bystander. It is, in many ways, the most affected organ in the body.

Third, the seven-to-ten-year window between the start of perimenopause and the end of early menopause is now understood as the most consequential window for lifelong bone, brain, and cardiovascular health that midlife offers. What happens in those years is not just about symptom management. It is about what your skeleton, your cognition, and your vasculature look like at seventy, eighty, ninety.

If that sounds like a lot of weight on a phase that, until recently, was barely mentioned in medical training — yes. That is exactly the point. And it is why so many clients arrive in clinic frustrated: they have been told for years that what they are experiencing is "just stress," "just ageing," "just normal," when in fact it is none of those things in isolation.

Let me walk you through what's actually going on.

The Brain on Fluctuating Estrogen

The single most under-recognised symptom cluster of perimenopause, in my experience, is the cognitive one. Brain fog. Word-finding difficulty. The sense that you are just slightly behind the conversation you used to lead. Sleep that has fragmented even though nothing else in life has changed. A shorter fuse, a more brittle stress response, a flatter emotional register.

The recent surveys are sobering: one in two women does not connect these symptoms to perimenopause at all. They attribute it to stress, parenting, aging, work, or — most damagingly — to themselves.

The mechanism is now well-mapped. Estrogen has profound effects on:

• Cerebral glucose metabolism. It supports the brain's ability to use glucose as fuel. As oestrogen declines, cerebral glucose uptake drops measurably. Some women's brains compensate by shifting toward ketone metabolism; others struggle. The "fuel-starved brain" is one part of the cognitive picture.

• Synaptic plasticity and BDNF. Estrogen promotes the production of brain-derived neurotrophic factor — the molecule that supports the formation of new neural connections. When BDNF drops, learning, memory consolidation, and verbal recall suffer.

• GABA and serotonin signalling. Mood and sleep effects are not coincidence. Estrogen and progesterone both modulate the calming neurotransmitter systems. Their decline destabilises sleep architecture and emotional regulation.

• The sleep-hot-flush loop. Vasomotor symptoms that wake you are not "just" annoying. Each one is a small autonomic surge that disrupts deep and REM sleep. Compounded over months, this is a profound cognitive and metabolic stressor in its own right.

When a patient tells me she "feels stupid" in her late forties, I take that very seriously. She is not stupid. Her brain is being asked to operate without the hormonal scaffolding it has run on for thirty years, and is doing so while sleeping poorly. The cognitive complaint is real, mechanistic, and — importantly — usually reversible.

The Bone Window You Cannot Reopen

Bone is the other tissue that loses its scaffolding when estrogen declines.

Estrogen restrains osteoclast activity — the cells that break bone down — while supporting osteoblast activity — the cells that build it. When estrogen falls, osteoclasts run unopposed for several years. Bone density loss accelerates dramatically in the first 5–7 years after the final period, particularly in the spine.

The clinical implication is uncomfortable but important: the bone you do not protect during perimenopause and early menopause is bone you may not be able to rebuild later. DEXA scanning at the start of perimenopause is no longer a "wait and see" recommendation in my clinic; it is a baseline measurement we want to have, so we can see what the trajectory actually is.

A few things make a measurable difference here:

• Resistance training, ideally twice a week, with progressive load

• Vitamin D adequacy (target serum 100–120 nmol/mL)

• Vitamin K2 (MK-7), magnesium, and adequate dietary calcium

• Protein intake at 1.2–1.6 g per kg, especially in women who have spent decades under-eating

The "just take calcium" advice of the 1990s is not enough. The mineral matters less than the matrix it is being deposited into, and the matrix is built by mechanical load and the right cofactors.

The HRT Renaissance — What's Actually Different Now

There is no way to write a balanced piece about perimenopause without addressing the HRT question, because the conversation has genuinely changed.

What is different now, compared to what your mother was probably told:

The hormones used. Body-identical estradiol (transdermal in most cases) and micronised progesterone have a different risk profile than the conjugated equine estrogens and synthetic progestins that drove the WHI concerns. Transdermal delivery, in particular, bypasses the liver-mediated clotting risks that gave oral estrogen its bad reputation.

The timing. Starting HRT within ten years of the final menstrual period and under sixty is associated with very different outcomes — including potential cardiovascular and cognitive benefit — than starting it twenty years late.

The framing. HRT is no longer being thought of as "for severe symptoms only." It is increasingly being thought of as a tool for protecting brain, bone, and cardiovascular health during the high-vulnerability window of perimenopause and early menopause.

This does not mean every woman should be on HRT. It does mean that the previous default — "tough it out, the alternatives are too risky" — is no longer evidence-based. The conversation has to be individualised. Personal and family history of breast cancer, cardiovascular risk, migraine pattern, current symptom burden, life-stage goals — all of it matters. 

What I would strongly suggest to any woman in perimenopause: find a clinician who has read the literature since the WHI re-analyses, not someone whose framework was set by the 2002 press cycle.

What Else Belongs in the Protocol

The protocol I run in clinic for perimenopausal clients typically includes:

• Adrenal and stress-system support. The adrenals are asked to pick up some of the hormonal slack after the ovaries step back — primarily through DHEA. The trouble is that the same precursor (pregnenolone) feeds both cortisol and DHEA pathways, and a decade of chronic stress preferentially shunts that precursor toward cortisol — the so-called pregnenolone steal. The result is a perimenopausal woman whose cortisol is up, DHEA is flat, and ovarian backup is therefore impoverished. Cortisol-rhythm testing (saliva or DUTCH), DHEA-S, adaptogenic herbs (rhodiola, ashwagandha — with the appropriate caveats around hyperthyroid and autoimmune patients), and sleep-architecture work all earn their keep here.

• Liver and gut clearance — the estrobolome. Estrogen does not just need to be produced; it needs to be properly cleared. The liver runs Phase I (CYP450 hydroxylation, where the 2-OH pathway is protective and the 4-OH and 16-OH pathways are more inflammatory) and Phase II (methylation, glucuronidation, sulphation) on every estrogen molecule before it heads to the gut for excretion. In the gut, certain bacteria produce beta-glucuronidase, which can re-activate estrogen that has already been packaged for excretion — sending it back into circulation. The "estrobolome" effect. So a woman can have normal serum estrogen and high tissue estrogen activity simultaneously. The fix sits at the gut–liver–hormone interface: methylated B12 and folate to support methylation, DIM or sulforaphane to nudge estrogen down the protective 2-OH pathway, calcium-d-glucarate to inhibit beta-glucuronidase, fibre to bind, and a clean-running gut to actually carry estrogen out.

• Blood sugar regulation. Insulin resistance worsens hot flushes, sleep, mood, and cardiovascular risk. Continuous glucose monitoring for 2–4 weeks is one of the most informative tools I run for midlife women, full stop.

• Mineral and nutrient correction. Iron and ferritin (often high now in non-menstruating women, not low), B12, vitamin D, magnesium, zinc — all commonly off-target in midlife and all of them produce symptoms that mimic "just menopause." HTMA adds another layer of pattern recognition: the copper–zinc dynamic in particular shifts in perimenopause, with copper rising as estrogen falls (estrogen and copper are bound up in the same regulatory loop), and the resulting copper-dominance can drive anxiety, sleep disruption, and skin changes that look hormonal but answer to mineral correction.

• Sleep, ruthlessly defended. Anything that protects the first half of the night — magnesium glycinate, glycine, low-dose melatonin if needed, blue-light hygiene, room temperature 17–19°C — pays dividends across every other system. Progesterone insufficiency particularly damages the first half of the night; this is often the single most clinically useful thing body-identical progesterone does, and patients feel it within a week.

The Reframe

Perimenopause is not a problem to push through. It is the most important hormonal-neurological-skeletal transition of a woman's adult life. The choices made in the seven to ten years around it — about HRT, about training, about nutrition, about sleep, about stress — show up thirty years later as either resilience or fragility.

The good news is that, finally, the science has caught up to what so many women have been telling their clinicians for decades. The brain fog is real. The sleep change is real. The mood shift is real. They are not character flaws. They are mechanisms. And mechanisms can be addressed.

If the symptoms are loud enough that they have brought you to read an article like this one, they are loud enough to be worth a proper, integrative, hormone-aware workup.

This article is educational and not a substitute for individualised medical care. HRT decisions should always be made with a qualified clinician who has reviewed your full history.

References

• Nature, 2025–2026 — The new science of menopause: emerging therapies

• Harvard Medical School — Women's Health and Menopause (WHAM) program 2026

• Levels Health, 2026 — Guide to Hormone Replacement Therapy

• TārāMD — Menopause, the Women's Health Initiative, and HRT

• Natural Awakenings, 2026 — Bone Health in Perimenopause and Beyond